Drug Trial Radar · NCT06118086
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
125
Planned (sponsor's estimate)
Start
Dec 20, 2023
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Remix TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
Conditions
- Adenoid Cystic Carcinoma
- Metastatic Adenoid Cystic Carcinoma
- Recurrent Adenoid Cystic Carcinoma
Interventions
REM-422Drug
* REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor * REM-422 will be administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of Treatment Emergent Adverse Events (TEAEs)Time frame: 18 months
- Overall Response Rate (ORR) in Phase 2 Confirmatory CohortTime frame: 18 months
- Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)Time frame: Assessed at the end of Cycle 1 for each participant
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
University of California San Francisco Helen Diller Comprehensive Cancer Center
San Francisco, California · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Dana Farber Cancer Research Institute
Boston, Massachusetts · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Centre Antoine Lacassagne
Nice, France · Recruiting
Institut de Cancerologie Gustave-Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.